- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2057-3804
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cardiotoxicity risk factors with immune checkpoint inhibitors ; volume:8 ; number:1 ; day:11 ; month:3 ; year:2022 ; pages:1-8 ; date:12.2022
Cardio-Oncology ; 8, Heft 1 (11.3.2022), 1-8, 12.2022
- Creator
-
Brumberger, Zachary L.
Branch, Mary E.
Klein, Max W.
Seals, Austin
Shapiro, Michael D.
Vasu, Sujethra
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40959-022-00130-5
- URN
-
urn:nbn:de:101:1-2022060514015527568034
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brumberger, Zachary L.
- Branch, Mary E.
- Klein, Max W.
- Seals, Austin
- Shapiro, Michael D.
- Vasu, Sujethra
- SpringerLink (Online service)
Other Objects (12)
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Cardiotoxicity during checkpoint inhibitor therapy in patients with advanced skin cancer
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Cardiotoxicity during checkpoint inhibitor therapy in patients with advanced skin cancer
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy
A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance
A comprehensive review on immune checkpoint inhibitors induced cardiotoxicity characteristics and associated factors
Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
Immune checkpoint inhibitor-induced cardiotoxicity in patients with lung cancer: a systematic review and meta-analysis
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Cardiotoxicity during checkpoint inhibitor therapy in patients with advanced skin cancer
Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors